Welcome to Cantargia

Cantargia AB is a research and development company based on the original discovery by Professor Thoas Fioretos and Dr. Marcus Järås at Lund University, Sweden. Cantargia is focused on developing a conceptually new therapy for the treatment of hematological malignancies (leukemia) by targeting a unique cell-surface receptor on leukemic stem cells.  Cantargia is also evaluating the therapeutic potential in solid tumors, malignant melanoma in particular.

Our primary goal is to improve the lives of patients by developing antibody therapeutics for eradication of malignant stem cells, the root of cancer.